Cel Sci (CVM) Cash from Financing Activities (2010 - 2026)
Cel Sci (CVM) posted Cash from Financing Activities of -$364461.0 for Q1 2026, up 44.25% sequentially from -$653773.0 in Q4 2025, and down 121.7% YoY from $1.7 million in Q1 2025.
Cel Sci (CVM) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Cel Sci has reported Cash from Financing Activities for 16 years, with the latest figure at -$364461.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 121.7% year-over-year to -$364461.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.6 million (up 13.91% YoY) and the FY2025 annual result came in at $23.4 million, up 19.79% from the prior year.
- Cash from Financing Activities grew to -$364461.0 in Q1 2026 per CVM's latest filing, from -$653773.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $13.8 million in Q3 2025 and troughed at -$653773.0 in Q4 2025.
- A 5-year average of $2.7 million and a median of $951563.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities sank 249.79% in 2022, then surged 6089.41% in 2023.
- Over 5 years, Cash from Financing Activities stood at $65410.0 in 2022, then soared by 6089.41% to $4.0 million in 2023, then advanced by 0.01% to $4.0 million in 2024, then slumped by 116.15% to -$653773.0 in 2025, then surged by 44.25% to -$364461.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$364461.0, -$653773.0, and $13.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | 8.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -364,461.00 |
| Mar 31, 2026 | -364,461.00 |
| Dec 31, 2025 | -653,773.00 |
| Dec 31, 2025 | -653,773.00 |
| Sep 30, 2025 | 13.84 Mn |
| Sep 30, 2025 | 13.84 Mn |
| Jun 30, 2025 | 3.81 Mn |
| Jun 30, 2025 | 3.81 Mn |
| Mar 31, 2025 | 1.68 Mn |
| Mar 31, 2025 | 1.68 Mn |
| Dec 31, 2024 | 4.05 Mn |
| Dec 31, 2024 | 4.05 Mn |
| Sep 30, 2024 | 9.19 Mn |
| Sep 30, 2024 | 9.19 Mn |
| Jun 30, 2024 | -322,303.00 |
| Jun 30, 2024 | -322,303.00 |
| Mar 31, 2024 | 6.60 Mn |
| Mar 31, 2024 | 6.60 Mn |
| Dec 31, 2023 | 4.05 Mn |
| Dec 31, 2023 | 4.05 Mn |